- Previous Close
50.65 - Open
50.58 - Bid 37.34 x 100
- Ask 64.83 x 100
- Day's Range
49.56 - 52.30 - 52 Week Range
20.08 - 57.28 - Volume
499,104 - Avg. Volume
670,815 - Market Cap (intraday)
2.131B - Beta (5Y Monthly) 1.06
- PE Ratio (TTM)
-- - EPS (TTM)
-3.07 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
70.62
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
www.tarsusrx.comRecent News: TARS
View MorePerformance Overview: TARS
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TARS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TARS
View MoreValuation Measures
Market Cap
2.13B
Enterprise Value
1.91B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.63
Price/Book (mrq)
9.49
Enterprise Value/Revenue
10.45
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-63.16%
Return on Assets (ttm)
-23.46%
Return on Equity (ttm)
-54.83%
Revenue (ttm)
182.95M
Net Income Avi to Common (ttm)
-115.55M
Diluted EPS (ttm)
-3.07
Balance Sheet and Cash Flow
Total Cash (mrq)
291.38M
Total Debt/Equity (mrq)
32.27%
Levered Free Cash Flow (ttm)
-50.48M